<DOC>
	<DOC>NCT00330915</DOC>
	<brief_summary>The purpose of this study is to help answer the following research questions: If the study drug Pemetrexed can help patients with rectal cancer; If molecular biological parameters are correlated respectively changing due to cytotoxic treatment with Pemetrexed; To evaluate adverse events</brief_summary>
	<brief_title>A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>no prior therapy for rectal cancer pathological/ cytological diagnosis of adenocarcinoma of the rectum. Patients must have operable rectal cancer that is amenable to surgery. adequate organ function Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1 signed informed consent at least 18 years of age surgically sterile, postmenopausal (women) or compliant with a medically approved contraceptive regimen during and for 6 months after the treatment. concurrent administration of any other antitumor therapy treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry serious concomitant systemic disorders previously completed or withdrawn from this study pregnant or breastfeeding second primary malignancy history of significant neurological or mental disorder, including seizures or dementia inability to interrupt aspirin or other nonsteroidal antoinflammatory drugs (NSAIDs) presence of clinically relevant third space fluid collections that cannot be controlled by drainage or other procedure prior to the study entry inability or unwillingness to take folic acid, vitamin B12 or dexamethasone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>